Rafael Holdings, Inc. (RFL) - Q2 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended January 31, 2025 (Fiscal Q2 2025). Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies, medical devices, and real estate. The Company operates through three segments: Healthcare, Infusion Technology, and Real Estate. A primary strategic focus is the planned merger with Cyclo Therapeutics, Inc. (CYTH), with the Company intending to fund Cyclo's Phase 3 clinical trial for Trappsol Cyclo upon closing.
Key Financial Metrics
| Metric | Three Months Ended Jan 31, 2025 | Six Months Ended Jan 31, 2025 |
|---|---|---|
| Total Revenue | $77,000 | $205,000 |
| Net Loss (Consolidated) | $(5,327,000) | $(14,538,000) |
| Net Loss Attributable to RFL | $(4,641,000) | $(13,647,000) |
| Loss Per Share (Basic/Diluted) | $(0.19) | $(0.57) |
| Cash and Cash Equivalents | $48,319,000 | $48,319,000 |
| Total Assets | $83,042,000 | $83,042,000 |
| Total Liabilities | $10,479,000 | $10,479,000 |
| Working Capital | $58,723,000 | $58,723,000 |
Material Changes vs. Prior Period
- Revenue: Total revenue increased to $77,000 for the quarter (from $68,000 in Q2 2024) and $205,000 for the six months (from $136,000 in the prior six months). This growth is driven by the Infusion Technology segment (Day Three), which generated $51,000 in revenue for the six months ended Jan 31, 2025, compared to zero in the prior year.
- Net Loss: The Company reported a net loss of $5.3 million for the quarter, a significant deterioration from a net income of $5.9 million in the same period last year. The six-month loss was $14.5 million compared to net income of $2.1 million in the prior year.
- Goodwill Impairment: A non-cash impairment charge of $3.05 million was recorded in the quarter ended January 31, 2025, related to the Infusion Technology segment (Day Three) following a triggering event due to operational reductions.
- Investment Volatility: Unrealized gains on the Cyclo Therapeutics investment swung from a $9.7 million gain in Q2 2024 to a $3.8 million loss for the six months ended Jan 31, 2025, reflecting market price fluctuations.
- Liquidity: Cash and cash equivalents increased significantly to $48.3 million from $2.7 million at July 31, 2024, primarily due to the sale of available-for-sale securities ($80.7 million proceeds) and proceeds from hedge fund withdrawals.
Guidance, Outlook, and Risks
- Mergers and Acquisitions: The Company is actively pursuing a merger with Cyclo Therapeutics. The Merger Agreement was amended to extend the closing deadline to March 31, 2025. Upon closing, Rafael intends to fund Cyclo's TransportNPC Phase 3 clinical trial up to a maximum of $25 million (including pre-closing funding).
- Subsequent Events: Following the period end, Rafael issued additional convertible notes to Cyclo totaling $4.5 million (Notes IX and X) with maturity dates of March 31, 2025. Additionally, Cornerstone Pharmaceuticals entered into an asset purchase agreement with Synhale Therapeutics.
- Operational Risks: The Infusion Technology segment (Day Three) reduced operations and recorded a full goodwill impairment. The Company is evaluating the prospects of Day Three's technology in light of regulatory conditions.
- Debt and Defaults: Certain Series C Convertible Notes of Cornerstone and an installment note payable related to Day Three are currently in default as they are beyond their maturity dates, though some have been amended or are subject to forbearance agreements.
- Liquidity Outlook: Management expects cash balances to be sufficient to meet obligations for at least the next 12 months.
Investor Verification Checklist
- Merger Status: Verify the progress of the Cyclo Therapeutics merger, specifically the receipt of required shareholder approvals and the effectiveness of the Form S-4 registration statement.
- Goodwill Impairment: Review the assumptions used in the quantitative goodwill impairment test for the Infusion Technology segment to understand the valuation of Day Three.
- Convertible Note Maturities: Monitor the status of the Cyclo Convertible Notes and Cornerstone Series C notes maturing in March 2025 to assess refinancing or conversion risks.
- Cash Burn Rate: Analyze the operating cash burn rate in the Healthcare segment, which has no revenue and relies on funding for clinical trials (LipoMedix, Cornerstone).
- Related Party Transactions: Review the concentration of revenue from related party tenants (IDT Corporation) and the terms of the forbearance agreements with Cornerstone creditors.